한글목차

인테그라제 억제제 시장은 2025년에는 164억 3,000만 달러, 2032년에는 242억 2,000만 달러에 이를 것으로 예측되며, 2025년부터 2032년까지 연평균 복합 성장률(CAGR) 5.7%로 성장할 것으로 예측됩니다.

인테그라제 억제제는 HIV/AIDS 치료에 사용되는 항 레트로 바이러스 약물 중 비교적 새로운 클래스입니다. 인테그라제 억제제는 HIV 바이러스 DNA의 감염된 세포의 염색체 DNA에 대한 통합을 차단하고 새로운 HIV 비리온의 증식을 차단합니다. 임상시험은 높은 효능과 양호한 인용성을 보여주었으며, 그 이후로 엘비테그라빌과 돌테그라빌과 같은 새로운 세대의 인테그라제 억제제가 개발되어 승인되었습니다. 테그라아제 억제제의 도입으로 HIV 관리의 치료 옵션은 크게 확대되었습니다.

시장 역학 :

세계의 인테그라제 억제제 시장의 성장은 주로 세계의 HIV/AIDS의 질병 부담 증가, HIV에 대한 항레트로바이러스 치료(ART)의 채택 확대, 인테그라제 억제제의 신제품 및 개량품의 도입에 의한 강력한 제품 파이프라인에 의해 제공됩니다. HIV/AIDS의 유병률 증가, 약물 개발의 진보, 인테그라제 억제제의 효능과 안전성은 예측 기간 동안 세계 인테그라제 억제제 시장의 성장을 가속 예상되는 주요 요인입니다. 선진국에서 항 레트로 바이러스 요법의 적용에 대한 정부의 호의적 이니셔티브는 유리한 기회를 가져옵니다. 시장은 시장 성장에 부정적인 영향을 미칠 수 있습니다.

이 보고서의 주요 특징

• 본 보고서는 세계의 인테그라제 억제제 시장을 상세하게 분석하여 2024년을 기준연도로 한 예측기간(2025-2032년) 시장 규모 및 CAGR을 제공합니다.
• 또한 각 부문의 잠재적인 수익 기회를 밝혀 이 시장의 매력적인 투자 제안의 매트릭스에 대해 설명하고 있습니다.
• 또, 시장 성장 촉진요인 및 억제요인이나 기회, 신제품의 상시나 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하는 경쟁 전략 등에 관한 중요한 고찰도 제공합니다.
• 세계의 인테그라제 억제제 시장에 있어서의 주요 기업 프로파일을, 기업 개요, 제품 포트폴리오, 주요한 하이라이트, 재무 실적, 전략 등의 이하의 파라미터에 근거해 제공합니다.
• 본 보고서의 통찰을 이용해, 마케팅 담당자나 기업의 경영진이, 장래의 제품 발매, 제휴, 시장 확대, 마케팅 전술에 관한, 충분한 정보에 근거한 의사 결정을 내릴 수 있습니다.
• '세계 인테그라제 억제제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해관계자에 대응하고 있습니다.
• 이해관계자는 세계의 인테그라제 억제제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.

목차

제1장 조사의 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의와 범위
• 주요 요약
• Coherent Opportunity Map(COM)

제3장 시장 역학, 규제, 동향의 분석

• 시장 역학
  • HIV/AIDS의 만연 증가, 약제 개발, 유효성·안전성의 진보
  • 고액의 치료비나 부작용 및 안전성에 대한 우려
  • 치료 프로파일이 개선된 인테그라제 억제제
• 영향 분석
• 주요 하이라이트
• 규제 시나리오
• 제품 출시/승인
• PEST 분석
• Porter's Five Forces 분석
• 기업 합병·인수(M&A) 시나리오

제4장 세계의 인테그라제 억제제 시장 : 신형 코로나 바이러스 감염증(COVID-19) 유행의 영향

• COVID-19의 역학
• 공급측과 수요측의 분석
• 경제에 미치는 영향

제5장 세계의 인테그라제 억제제 시장 : 약제별(2020-2032년)

• 라르테그라빌
• 돌테그라빌
• 엘비테그라빌
• 빅테그라빌
• 기타(카보테그라빌 등)

제6장 세계의 인테그라제 억제제 시장 : 투여 경로별(2020-2032년)

• 오랄
• 정맥내
• 기타

제7장 세계의 인테그라제 억제제 시장 : 유통 채널별(2020-2032년)

• 병원 약국
• 소매 약국
• 온라인 약국

제8장 세계의 인테그라제 억제제 시장 : 지역별(2020-2032년)

• 북미
  • 미국
  • 캐나다
• 유럽
  • 독일
  • 영국
  • 스페인
  • 프랑스
  • 이탈리아
  • 러시아
  • 기타 유럽
• 아시아태평양
  • 인도
  • 중국
  • 일본
  • 호주
  • ASEAN
  • 한국
  • 기타 아시아태평양
• 라틴아메리카
  • 브라질
  • 아르헨티나
  • 멕시코
  • 기타 라틴아메리카
• 중동
  • GCC
  • 이스라엘
  • 기타 중동
• 아프리카
  • 북아프리카
  • 중앙 아프리카
  • 남아프리카

제9장 경쟁 구도

• Gilead Sciences
• ViiV Healthcare group
• Merck & Co., Inc
• GlaxoSmithKline PLC
• Bristol-Myers Squibb Company
• Johnson & Johnson
• AbbVie Inc
• Janssen Pharmaceuticals, Inc
• Theratechnologies Inc
• Shionogi & Co., Ltd
• Viatris Inc.

제10장 섹션

• 분석 방법
• 출판사에 대해

영문목차

Integrase Inhibitors Market is estimated to be valued at USD 16.43 Bn in 2025 and is expected to reach USD 24.22 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.7% from 2025 to 2032.

Integrase inhibitors are a relatively new class of antiretroviral drugs used for the treatment of HIV/AIDS. They work by specifically inhibiting HIV integrase, a retroviral enzyme that is essential for the replication of HIV's genome in host cells. Integrase inhibitors prevent integration of HIV viral DNA into the chromosomal DNA of the infected cells, thus blocking the propagation of new HIV virions. The first generation integrase inhibitor raltegravir was approved in 2007, offering a novel mechanism of action in suppressing HIV replication. It demonstrated high efficacy and good tolerability in clinical trials. Since then, newer generations of integrase inhibitors like elvitegravir and dolutegravir have been developed and approved. These agents have shown improved effectiveness and tolerability profiles over existing anti-HIV therapies. The introduction of integrase inhibitors has significantly expanded treatment options for HIV management. Integrase Inhibitors are primarily used in the treatment of HIV/AIDS by inhibiting the activity of the viral enzyme called integrase, thereby preventing the integration of the viral DNA into the host cell's DNA.

Market Dynamics:

The global integrase inhibitors market growth is primarily driven by the rising HIV/AIDS disease burden worldwide, increasing adoption of antiretroviral treatment (ART) for HIV, and robust product pipeline with introduction of newer and improved integrase inhibitor drugs. Increasing prevalence of HIV/AIDS, advancements in drug development, efficacy and safety of integrase inhibitors are major factors expected to drive growth of the global integrase inhibitors market during the forecast period. Favorable government initiatives in developed nations regarding coverage of antiretroviral therapy presents lucrative opportunities. However, the market growth can be negatively impacted by the emergence of drug-resistant strains of HIV and high costs of integrase inhibitor therapies. Key market players are engaged in R&D of long-acting injectable/oral formulations to increase adherence to treatment and drive revenue opportunities.

Key features of the study:

• This report provides in-depth analysis of the global integrase inhibitors market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global integrase inhibitors market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Gilead Sciences, ViiV Healthcare group, Merck & Co., Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Janssen Pharmaceuticals, Inc., Theratechnologies Inc., Shionogi & Co., Ltd., and Viatris Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global integrase inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global integrase inhibitors market.

Detailed Segmentation:

• By Drug:
  • Raltegravir
  • Dolutegravir
  • Elvitegravir
  • Bictegravir
  • Others (Cabotegravir, etc.)
• By Route of Administration:
  • Oral
  • Intravenous
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Gilead Sciences
  • ViiV Healthcare group
  • Merck & Co., Inc.
  • GlaxoSmithKline PLC
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • AbbVie Inc.
  • Janssen Pharmaceuticals, Inc.
  • Theratechnologies Inc.
  • Shionogi & Co., Ltd.
  • Viatris Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Integrase Inhibitor, By Drug
  • Market Integrase Inhibitor, By Route of Administration
  • Market Integrase Inhibitor, By Distribution Channel
  • Market Integrase Inhibitor, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing prevalence of HIV/AIDS, advancements in drug development, efficacy and safety
  • High Treatment Costs, Side Effects and Safety Concerns
  • Integrase Inhibitors with improved therapeutic profiles.
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Integrase Inhibitors Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Integrase Inhibitors Market, By Drug, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Raltegravir
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
• Dolutegravir
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
• Elvitegravir
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
• Bictegravir
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
• Others (Cabotegravir, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)

6. Global Integrase Inhibitors Market, By Route of Administration, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)

7. Global Integrase Inhibitors Market, By Distribution Channel, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Bn)

8. Global Integrase Inhibitors Market, By Region, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
    • India
    • China
    • Japan
    • Australia
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (US$ Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Gilead Sciences
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• ViiV Healthcare group
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co., Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline PLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Janssen Pharmaceuticals, Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Theratechnologies Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Shionogi & Co., Ltd
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Viatris Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

10. Section

• Research Methodology
• About us